NCT03225989View on ClinicalTrials.gov

Trial Investigating an Immunostimulatory Oncolytic Adenovirus for Cancer

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

47

Participants

Timeline

Start Date

March 1, 2018

Primary Completion Date

August 22, 2023

Study Completion Date

August 22, 2023

Conditions
Pancreatic AdenocarcinomaOvarian CancerBiliary CarcinomaColorectal Cancer
Interventions
DRUG

LOAd703

Oncolytic adenovirus serotype 5/35 encoding TMZ-CD40L and 4-1BBL

Trial Locations (2)

75185

Uppsala University Hospital, Uppsala

141 86

Karolinska University Hospital, Huddinge, Stockholm

Sponsors

Lead Sponsor

Lokon Pharma AB
All Listed Sponsors
collaborator

Uppsala University

OTHER

lead

Lokon Pharma AB

INDUSTRY

NCT03225989 - Trial Investigating an Immunostimulatory Oncolytic Adenovirus for Cancer | Biotech Hunter | Biotech Hunter